Immuno-Oncology

Eric Smith, MD, PhD, discusses recently reported phase II data combining elotuzumab (Empliciti) with lenalidomide (Revlimid) and dexamethasone.

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

Five of 8 patients with metastatic urothelial cancer benefited from the combination of ipilimumab and nivolumab after having no response to single-agent nivolumab.

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses next steps for a phase I/II study of brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) in patients with relapsed or refractory Hodgkin lymphoma.

Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.

Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

2017 is poised to be another pivotal year in non–small cell lung cancer, given the exciting advances in the field at the end of last year.

A group of doctors and other healthcare industry professionals have set out to develop a more efficient tool for assessing the true value of immuno-oncology drugs.

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.

Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses new combination regimens for patients with melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the advancements that have recently taken place in immunotherapy in the field of melanoma.

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

John Hunter, PhD, and Maya Kotturi, PhD, answer key questions about TIGIT as a target for anticancer therapy and the current development of TIGIT-targeting drugs.

Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

As researchers continue to identify a growing number of immune checkpoints as targets for anticancer therapy, the recently discovered TIGIT pathway is emerging as a promising new avenue for exploration.

Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.